Cargando…
Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?
BACKGROUND: Sickle cell disease (SCD) is one of the most prevalent hemoglobinopathies that affects around 275,000 neonates annually. Until 2017, hydroxyurea was the only available drug for SCD treatment. Later on, L‐glutamine and crizanlizumab have shown promising results in SCD therapy. OBJECTIVES:...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213830/ https://www.ncbi.nlm.nih.gov/pubmed/35774831 http://dx.doi.org/10.1002/hsr2.713 |